Skip to main content
//empty //empty

Quebec and Newfoundland and Labrador said on Wednesday they would not allow the sale of cannabis vapes, just weeks before the start of marijuana derivatives sales, as concerns linger about a possible connection between the vaping products and severe lung disease

“We will not be selling vaping products on January 1,” Fabrice Giguère, a spokesman for the Société québécoise du cannabis, which is responsible for marijuana sales in the province, said by e-mail, adding the province had not officially announced its stance.

All of Quebec’s legal cannabis stores are run by the provincial government, while Newfoundland and Labrador’s stores are private.

Story continues below advertisement

Earlier on Wednesday, Newfoundland and Labrador, which as Canada’s easternmost province was the first to kick off sales of legal cannabis last year, said it would not allow cannabis vape products, but would review the decision in light of any new clinical evidence.

There have been 11 cases of severe lung illnesses in Canada related to vaping, according to data from the Canadian government, which has said it is investigating the cause. Three have been in Quebec, and none in Newfoundland & Labrador.

The U.S. Centers for Disease Control and Prevention on Nov. 21 identified vitamin E acetate, an additive that is often mixed with marijuana oil in the illicit cannabis market, as a “chemical of concern.”

“The intent of the decision is to protect the health of the people in this province until there is more evidence about the connection between cannabis vaping products and severe lung disease,” the Newfoundland and Labrador government said in a statement.

Follow related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies